How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study
Open Access
- 15 October 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (20) , 7311-7321
- https://doi.org/10.1158/1078-0432.ccr-05-0560
Abstract
Purpose: Predicting late effects in patients treated with radiation therapy by assessing in vitro radiation-induced CD4 and CD8 T-lymphocyte apoptosis can be useful in individualizing treatment.Keywords
This publication has 39 references indexed in Scilit:
- Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast CancerCancer Research, 2005
- Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate GenesCancer Research, 2004
- Urokinase-Type Plasminogen Activator System in Breast CancerCancer Research, 2004
- Plasma MMP‐9 (92 kDa‐MMP) activity is useful in the follow‐up and in the assessment of prognosis in breast cancer patientsInternational Journal of Cancer, 2003
- MDC-9 (ADAM-9/Meltrin γ) Functions as an Adhesion Molecule by Binding the αvβ5 IntegrinBiochemical and Biophysical Research Communications, 2001
- The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancerEuropean Journal Of Cancer, 1997
- ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions.The Journal of cell biology, 1995
- Statistical analysis of proliferative index data in clinical trialsStatistics in Medicine, 1994
- Oestrogen receptor content and cancer cell/stroma ratio in mammary carcinomaAPMIS, 1988
- Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. workshop, held on 16–17 March, 1979, in the Netherlands Cancer InstitutePublished by Elsevier ,1980